The BioHub Podcast

🚨Medical Device Quality Manager – New Jersey – Urgent 🚨 I have just partnered with a Class II Device company who are looking to add a hands on Quality Manager to their team, below are the following requirements and job details: - Works closely with the Global Chief Operations Officer as well as the President & CEO - Oversees all quality assurance efforts to ensure all products are of highest quality, free from any defects and compliant to current applicable regulations (FDA, ISO13485, & MDSAP) - Plan, develop, and direct quality assurance policies, programs, and initiatives. - Enforce quality assurance policies, procedures, and applicable government regulations. Salary - $120-140k per annum depending on experience plus bonus and benefits. Reach out for further information on d.willoughby@avetixgroup.com #13485 #Quality #MDSAP #Opportunity #Career #Medical #Hiring

🎙 The BioHub Episode with Amit Kumar is LIVE! 🎙 In this episode, we sit down with Amit Kumar, Chairman, President and CEO at Anixa Biosciences, Inc. Biosciences We're excited to dive into his journey, the challenges and successes along the way, and what's next for Anixa and the broader biotech space. 👉 Catch the full episode via the link in the comments

📊 𝗤𝟯 𝗙𝗶𝗻𝗮𝗻𝗰𝗶𝗮𝗹 𝗥𝗲𝗽𝗼𝗿𝘁𝘀 📊 Financial reporting season is upon us and over the past couple of days we have started seeing some positive and promising figures emerging from the industry, highlighting the strength and growth of the global TIC sector. See below for key figures and upcoming dates for financial reports: Eurofins 9M Revenue - €5.142B (+6.7% vs 9M '23) EU Organic Growth - 9M '24 (5.4%), Q3 '24 (5.1%) NAM Organic Growth - 9M '24 (3.9%), Q3 '24 (2.0%) ROW Organic Growth - 9M '24 (8.6%), Q3 '24 (10.0%) Bureau Veritas Group Q3 Revenue - €1.547B (+8.8% YoY) Q3 Organic Growth - 13.0% YTD Organic Growth - 10.5% SGS - October 25th (market open) UL Solutions - November 5th (market open) #TIC #growth #earnings #reports

Alpha-9 Oncology Inc. Announces $175 Million Oversubscribed Series C Financing to Advance Robust Clinical Pipeline of Radiopharmaceuticals to meaningfully improve the treatment of people living with cancer The Series C was led by Lightspeed and Ascenta Capital with participation from new top-tier investor syndicate and existing investors. Congrats to all involved! David Hirsch, Stephen Mitchener, Alison Fleming, Matthias Jaffé, Ovid Trifan

🎙 The BioHub Episode with Daniel Couto is LIVE! 🎙 The BioHub Podcast introduces a new host, me, Rebekah Deane! In this episode, I sit down with Daniel Couto, COO of Vedanta Biosciences, Inc. to explore their cutting edge techniques within the microbiome space. Key Highlights: 💥 They built their own CDMO within their company to meet unmet needs within microbiome. ⛔ Challenges being faced in the microbiome space and how the market is evolving This episode is an exciting dive into the microbiome space, as this is a space to watch!! 👀 👉 Catch the full episode via the link in the comments #TheBioHub #podcast #Biotech #microbiome #danielcouto

1 Year at Avetix – The biggest and best decision of my career! 🎉 Rewind to when I was making the decision—it definitely felt like a risk, but deep down, I always knew I was going to do something like this. Thomas Hall convinced me that he was the guy to do it with, and he was absolutely right! For context, we didn’t know each other before Avetix Group, but after six months of conversations, it became crystal clear: this was a journey worth taking, and Tom was the partner to take it with. I feel super privileged he felt the same way. We share the same mindset, and we both know the sky’s the limit in what we can achieve together (we’re already doing it! 🚀) Fast forward to today, and the past year has been nothing short of life-changing. I’ve done things I never thought possible, both in and out of work. (I’m doing an Ironman! 😅 🏃♂️🚴♂️🏊♂️) Professionally, we’ve been breaking barriers left and right. The biotech team—just 3 people—has achieved incredible results this quarter: 💥 £500k at 3rd, final, and placement 💥 £120k at 1st 💥 Plus an extra £500k at sourcing—all in exclusive and retained roles. What once felt like a risk is now a well-oiled machine with cash in the bank, record-breaking achievements, an amazing team 👏, and a vision for even more success ahead. I can’t imagine how much I’d regret it if I hadn’t taken the leap. It’s true what they say: 𝘠𝘰𝘶 𝘮𝘪𝘴𝘴 100% 𝘰𝘧 𝘵𝘩𝘦 𝘴𝘩𝘰𝘵𝘴 𝘺𝘰𝘶 𝘥𝘰𝘯’𝘵 𝘵𝘢𝘬𝘦. 🎯 Here’s to the future with this incredible team and to all the exciting challenges still ahead! 🚀 Here we are just a year apart 😀 PS: This is still the best time to get involved at Avetix. Opportunities are at their peak when we’re early, and you can grow your team with us. If you’re a top biller, imagine what you can build with our proposition!

Just in this morning, the following roles in TIC Europe! x2 Lead Food Auditor Roles (France) -Strong background working with ISF & BRC Food Safety schemes -2+ years experience working for a Certification Body -Ability to travel throughout France, Belgium & Luxembourg x3 Lead Auditor Medical Device (Non-Active) France - Strong background working with MDSAP/EU MDR Audits - Experience with non-active medical devices - Extensive knowledge of MDN Codes in compliance with MDCG 2019-14 Please reach out to d.willoughby@avetixgroup.com to learn more #TIC #qualityassurance #medicaldevice #foodsafety #audit #QARA #60601 #62304

📈 We are absolutely flying at Avetix!   ✅ Hired another BU Leader (£800K Biller), starting in a couple of weeks. ✅ Well on track for our £1M Q4 Target (despite only 9 people in the business, most of which joined this year), with £500K at Offer/Final stage. ✅ Signed Exclusive Partnerships with 3 Top US VC’s – all have huge growth plans for their portfolio. ✅ 2 X Terms signed with Big Pharma.   We’re entering an exciting growth phase and are on the lookout for top performers in Leeds/London to join us on this journey. Shoot me a message if you feel like you’ve hit a ceiling, don’t miss the boat!

🚀 𝐄𝐱𝐜𝐢𝐭𝐢𝐧𝐠 𝐎𝐩𝐩𝐨𝐫𝐭𝐮𝐧𝐢𝐭𝐢𝐞𝐬 𝐢𝐧 𝐭𝐡𝐞 𝐓𝐞𝐬𝐭𝐢𝐧𝐠, 𝐈𝐧𝐬𝐩𝐞𝐜𝐭𝐢𝐨𝐧 & 𝐂𝐞𝐫𝐭𝐢𝐟𝐢𝐜𝐚𝐭𝐢𝐨𝐧 𝐈𝐧𝐝𝐮𝐬𝐭𝐫𝐲! 🚀 This week, I am thrilled to announce that we have partnered with the leading North American Quality Assurance provider for Electrical, Energy & Battery work in the TIC space on a multi-hire project! Current vacancies with said client: - x3 Lead Technical Specialist - Salary circa $110k-130k plus relocation if required - x1 Technical Lead/Manager - Salary circa $150k-180k per annum plus relocation if required I am looking to speak with Energy Storage Systems / Battery Storage Systems focused professionals in North America who are well versed in the following standards: UL 9540 / 9540A & B, IEC 62933-5-2 Inverters power conversion and / or grid code I-EEE 1547, UL 1741, UL 1741 SB, IEC 62109, UL 3141 Energy Management UL 916 Switchgear UL 891, IEEE C37.100.1, IEEE C37.20 series Interested or know someone who might be? Let’s connect! 📩 #TIC #Hiring #Career #Opportunity

✨ 29 𝐄𝐩𝐢𝐬𝐨𝐝𝐞𝐬, 29 𝐈𝐧𝐜𝐫𝐞𝐝𝐢𝐛𝐥𝐞 𝐁𝐢𝐨𝐭𝐞𝐜𝐡 & 𝐏𝐡𝐚𝐫𝐦𝐚 𝐄𝐱𝐞𝐜𝐬! ✨ Hosting The BioHub Podcast has been an amazing journey. Not only have I learned so much, but some key themes keep emerging from my conversations with top biotech and pharma leaders. Here are the topics that come up time and time again: 🔍 𝐀𝐈: 𝐓𝐡𝐞 𝐈𝐧𝐝𝐮𝐬𝐭𝐫𝐲’𝐬 𝐁𝐮𝐳𝐳𝐰𝐨𝐫𝐝 Yes, it’s that buzzword again—AI! Everyone’s talking about it, trying to understand it, and figuring out how to get ahead with it. From drug discovery to data management, AI is changing the game for biotech. Want a deep dive into AI? Check out Episode 16 with Angelo Stracquatanio III—we explore how AI is reshaping the industry. 👥 𝐂𝐮𝐥𝐭𝐮𝐫𝐞 𝐄𝐚𝐭𝐬 𝐒𝐭𝐫𝐚𝐭𝐞𝐠𝐲 𝐟𝐨𝐫 𝐁𝐫𝐞𝐚𝐤𝐟𝐚𝐬𝐭 With layoffs, funding challenges, and more, it’s a tough time for many in biotech. But the message is clear: To keep your best people, you need to create a great environment where they can thrive. Culture is key—especially when things get tough. 💡 𝐇𝐨𝐰 𝐭𝐨 𝐌𝐚𝐤𝐞 𝐈𝐭 𝐢𝐧 𝐓𝐡𝐢𝐬 𝐖𝐨𝐫𝐥𝐝 Find your passion, work for what you believe in, and if you’re not doing that, find a way to understand why your work matters. Meet your patients, connect with the impact—that’s what keeps the drive alive. 📊 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐃𝐚𝐭𝐚 𝐢𝐬 𝐊𝐢𝐧𝐠 In a time of tight financing, if you don’t have clinical data, you need rock-solid preclinical science and big names behind you. But let’s be honest—clinical data is still the trump card! Companies with exceptional data and proven results are the ones winning in this tough market. 💼 𝐀𝐫𝐞 𝐕𝐂𝐬 𝐁𝐚𝐜𝐤 𝐢𝐧 𝐭𝐡𝐞 𝐆𝐚𝐦𝐞? Some VCs may have hit pause, but they’re starting to come back—and that’s a huge win for early-stage innovation. There’s still optimism out there, and we need that drive from startups to push boundaries and fuel progress. 🎢 𝐁𝐢𝐨𝐭𝐞𝐜𝐡 𝐢𝐬 𝐀𝐥𝐰𝐚𝐲𝐬 𝐚 𝐑𝐨𝐥𝐥𝐞𝐫𝐜𝐨𝐚𝐬𝐭𝐞𝐫 If there’s one thing that’s certain, it’s that biotech is a wild ride. Every exec I’ve spoken to has their own stories of challenges and wins. It’s part of what makes biotech so exciting—never a dull moment! What does everyone think? Have I missed some big ones? #BioTech #Pharma #AI #CultureMatters #ClinicalData #VC #BiotechInnovation #TheBioHub